Proteolytic Inhibition in Regulating the Insulin-Like Growth Factor-Binding Proteins in Prostate Cancer

Prostate-Specific Antigen (PSA), a serine protease, is believed to regulate the actions of extracellular matrix proteins such as fibronectin and Insulin-like Growth Factor-Binding Proteins (IGFBPs), possible factors involved in tumor progression and metastasis. Two phosphonate ester derivatives Cbz-(4-AmPhGly)p(OPh)2 (Inh I) and Cbz- (4-AmPhe)p(OPh)2 (Inh II), first mechanism-based inhibitors for PSA were synthesized using Oleksyszyn oxidation reaction, and their inhibitory activities on cleaving fibronectin (both human and bovine) and IGFBPs were investigated. To elucidate the role of PSA in the development and progression of prostate cancer, the regulation of the PSA activity on these two physiological substrates was clearly illustrated by modulating the concentrations of inhibitors, i.e. cleavages of both fibronectin and IGFBPs by PSA are inhibited by structure specific designed diphenyl phosphonate esters, consistent with the putative degradation. The inhibition data of two synthetic phosphonate ester derivatives, as lead compounds, will facilitate the development of more specific inhibitors of PSA activity, likely to modulate the physiological control of the IGF in human prostatic cell growth.

[1]  S. Nemoto,et al.  Ageing and the mystery at Arles , 2004, Nature.

[2]  L. Giudice,et al.  Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. , 1993, Growth regulation.

[3]  T. Rohan,et al.  Role of the insulin-like growth factor family in cancer development and progression. , 2000, Journal of the National Cancer Institute.

[4]  R. Stock,et al.  Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. , 2002, Journal of the National Cancer Institute.

[5]  D. Peehl,et al.  Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease. , 1994, The Journal of endocrinology.

[6]  U Winkler,et al.  Synthesis and evaluation of diphenyl phosphonate esters as inhibitors of the trypsin-like granzymes A and K and mast cell tryptase. , 1998, Journal of medicinal chemistry.

[7]  J. Fowlkes,et al.  Characterization of Glycosaminoglycan-binding Domains Present in Insulin-like Growth Factor-binding Protein-3* , 1996, The Journal of Biological Chemistry.

[8]  R. Norton,et al.  IGF-binding proteins – the pieces are falling into place , 2005, Trends in Endocrinology & Metabolism.

[9]  M. Webber,et al.  Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  S. Chernausek,et al.  Insulin-like growth factor-binding protein-3 (IGFBP-3) concentration in rat Sertoli cell-conditioned medium is regulated by a pathway involving association of IGFBP-3 with cell surface proteoglycans. , 1994, Endocrinology.

[11]  S. Afford,et al.  Differential cellular synthesis of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 within human liver. , 1994, The Journal of clinical endocrinology and metabolism.

[12]  M. Rechler,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II Stimulate Apoptosis in Human Prostate Cancer Cells* , 2002, The Journal of Biological Chemistry.

[13]  B. Katzenellenbogen,et al.  Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. , 1990, Endocrinology.

[14]  J. Powers,et al.  Irreversible inhibition of serine proteases by peptide derivatives of (alpha-aminoalkyl)phosphonate diphenyl esters. , 1991, Biochemistry.

[15]  A. Grimberg P53 and IGFBP-3: apoptosis and cancer protection. , 2000, Molecular genetics and metabolism.

[16]  B. Cooperman,et al.  The preparation and catalytic properties of recombinant human prostate-specific antigen (rPSA). , 2000, Biochimica et biophysica acta.

[17]  J. Weiler,et al.  IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. , 1995, Growth regulation.

[18]  D. Leroith,et al.  The new kid on the block(ade) of the IGF-1 receptor. , 2004, Cancer cell.

[19]  H. Lilja,et al.  Enzymatic action of prostate‐specific antigen (PSA or hK3): Substrate specificity and regulation by Zn2+, a tight‐binding inhibitor , 2000, The Prostate.

[20]  J. Holaday,et al.  Antiangiogenic activity of prostate-specific antigen. , 1999, Journal of the National Cancer Institute.

[21]  D. Tindall,et al.  In situ hybridization of prostate-specific antigen mRNA in human prostate. , 1990, The Journal of urology.

[22]  M. Hendrix,et al.  Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. , 1994, Science.

[23]  B. Cooperman,et al.  Design of synthetic hexapeptide substrates for prostate-specific antigen using single-position minilibraries. , 1999, The journal of peptide research : official journal of the American Peptide Society.

[24]  S. Hankinson,et al.  Insulin-like growth factors and neoplasia , 2004, Nature Reviews Cancer.

[25]  R B Brandt,et al.  Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes. , 1987, Biochemical medicine and metabolic biology.

[26]  H. Lilja A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[27]  I. Campbell,et al.  Structure of the fibronectin type 1 module , 1990, Nature.

[28]  H. Lilja,et al.  Molecular cloning of human prostate specific antigen cDNA , 1987, FEBS letters.

[29]  D. Farquhar,et al.  Biologically reversible phosphate-protective groups. , 1983, Journal of pharmaceutical sciences.

[30]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[31]  L. Giudice,et al.  Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. , 1992, The Journal of clinical endocrinology and metabolism.

[32]  J. Clements,et al.  The Tissue Kallikrein Family of Serine Proteases: Functional Roles in Human Disease and Potential as Clinical Biomarkers , 2004, Critical reviews in clinical laboratory sciences.

[33]  E. De Clercq,et al.  cycloSal-2',3'-dideoxy-2',3'-didehydrothymidine monophosphate (cycloSal-d4TMP): synthesis and antiviral evaluation of a new d4TMP delivery system. , 1998, Journal of medicinal chemistry.

[34]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[35]  G. Murphy,et al.  Prostate antigen: A new potential marker for prostatic cancer , 1981, The Prostate.

[36]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[37]  E. Webb,et al.  Non-Inverted Versus Inverted Plots in Enzyme Kinetics , 1959, Nature.

[38]  J. Powers,et al.  Novel amidine-containing peptidyl phosphonates as irreversible inhibitors for blood coagulation and related serine proteases. , 1994, Journal of medicinal chemistry.

[39]  P. Cohen,et al.  Insulin-like Growth Factor (IGF)-binding Protein-3 Induces Apoptosis and Mediates the Effects of Transforming Growth Factor-β1 on Programmed Cell Death through a p53- and IGF-independent Mechanism* , 1997, The Journal of Biological Chemistry.

[40]  R. Baxter,et al.  Cellular actions of the insulin-like growth factor binding proteins. , 2002, Endocrine reviews.

[41]  M. Schachter Kallikreins (kininogenases)--a group of serine proteases with bioregulatory actions. , 1979, Pharmacological reviews.

[42]  S. Mohan,et al.  IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. , 2002, The Journal of endocrinology.

[43]  R. Maronpot,et al.  Inhibition of the enzymatic activity of prostate‐specific antigen by boric acid and 3‐nitrophenyl boronic acid , 2003, The Prostate.

[44]  T. Stamey,et al.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. , 1988, The New England journal of medicine.

[45]  L. Murphy,et al.  Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. , 2001, The Journal of clinical endocrinology and metabolism.

[46]  S A Newman,et al.  Different roles for fibronectin in the generation of fore and hind limb precartilage condensations. , 1995, Developmental biology.

[47]  A. Hoeflich,et al.  Insulin-like growth factor (IGF)-I stimulates cell proliferation and induces IGF binding protein (IGFBP)-3 and IGFBP-5 gene expression in cultured growth plate chondrocytes via distinct signaling pathways. , 2005, Endocrinology.

[48]  J. Silha,et al.  Insulin-like growth factor binding proteins in development. , 2005, Advances in experimental medicine and biology.

[49]  M. Papa,et al.  Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. , 1993, The Journal of clinical endocrinology and metabolism.

[50]  D. Farquhar,et al.  Bioreversible phosphate protective groups: Synthesis and stability of model acyloxymethyl phosphates , 1984 .